Your stomach hurts after almost every meal. You have had endoscopies, ultrasounds, and blood work � all normal. Your doctor says there is nothing wrong, but the pain is real. This is functional dyspepsia, and your vagus nerve is likely the missing link.

Functional dyspepsia (FD) is a chronic disorder characterized by symptoms originating from the upper abdomen � pain, burning, early satiety, or postprandial fullness � in the absence of any identifiable structural disease on endoscopy. FD is classified as a disorder of gut-brain interaction (DGBI).

It affects 10-20% of the global population and accounts for a significant proportion of gastroenterology consultations. Women are affected more often than men, and it most commonly begins in early to mid-adulthood (Frontiers in Neuroscience, 2022).

Key Takeaways

  • FD is a real, common condition � not "all in your head"
  • Two subtypes exist: EPS (pain) and PDS (fullness), with different mechanisms
  • Vagal dysfunction underlies both impaired accommodation and visceral hypersensitivity
  • Diagnosis requires ruling out structural disease with endoscopy
  • Treatment is multimodal: PPIs, prokinetics, neuromodulators, psychological therapy, dietary changes
  • Transcutaneous vagus nerve stimulation (taVNS) is an emerging evidence-based treatment

Last updated: July 28, 2026 � Reviewed by Dr. Sarah Mitchell, MD, FAASM

What Is Functional Dyspepsia?

Functional dyspepsia (FD) is a chronic disorder characterized by symptoms originating from the upper abdomen � pain, burning, early satiety, or postprandial fullness � in the absence of any identifiable structural disease. Endoscopy, imaging, and laboratory tests are normal. FD is classified as a disorder of gut-brain interaction (DGBI). It affects 10-20% of the global population (Frontiers in Neuroscience, 2022).

The Two Subtypes: EPS and PDS

The Rome IV criteria divide FD into two subtypes. Epigastric Pain Syndrome (EPS) features pain or burning in the upper abdomen that is not exclusively postprandial, driven by visceral hypersensitivity. Postprandial Distress Syndrome (PDS) features fullness and early satiety after meals, driven by impaired gastric accommodation. These frequently overlap.

The Vagus Nerve in FD: Impaired Accommodation and Visceral Hypersensitivity

The vagus nerve plays two distinct roles in FD. In approximately 30% of patients, vagal efferent signaling to the stomach is reduced, causing impaired gastric accommodation � the stomach's fundus fails to relax during eating, producing early satiety and postprandial pain (Frontiers in Neuroscience, 2022).

In other patients, vagal afferent nerves become hypersensitive � normal stomach distension is registered as pain. The dual nature of vagal dysfunction in FD (too little motor signaling, too much sensory signaling) explains why treatment approaches must target both aspects.

Causes and Risk Factors

Risk factors include acute gastroenteritis (post-infectious FD), psychological stress, altered gut microbiota, duodenal inflammation, genetic predisposition (GNB3, SERT gene variants), and female sex.

Diagnosis

FD is diagnosed by the presence of Rome IV criteria plus absence of structural disease on upper endoscopy. The workup typically includes upper endoscopy with H. pylori biopsies, abdominal ultrasound, blood work (CBC, celiac serology, thyroid function), and gastric emptying study if gastroparesis is suspected.

Treatment Options

First-Line Pharmacotherapy

Proton pump inhibitors for EPS, prokinetics (domperidone, itopride, acotiamide) for PDS, and H. pylori eradication if present.

Second-Line Pharmacotherapy

Buspirone (5-HT1A agonist that enhances gastric accommodation), low-dose tricyclic antidepressants (10-25 mg) for visceral hypersensitivity, mirtazapine for improved accommodation and appetite, and SSRIs for comorbid anxiety.

Psychological Therapies

Cognitive behavioral therapy, gut-directed hypnotherapy, and mindfulness training have Level 1 evidence for FD symptom reduction, comparable to pharmacotherapy (Complement Ther Med, 2025).

Transcutaneous Vagus Nerve Stimulation for FD

Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive treatment that directly targets the underlying vagal dysfunction. A 2024 randomized trial found that both 10 Hz and 25 Hz taVNS significantly improved FD symptoms compared to sham, with improvements in gastric accommodation and vagal activity (Gastroenterology Advisor, 2025).

A 2025 systematic review and meta-analysis of 6 trials confirmed that taVNS significantly improves FD symptoms, quality of life, and anxiety scores with a good safety profile (Complement Ther Med, 2025).

Dietary and Lifestyle Strategies

Small, frequent meals; low-fat diet; avoiding trigger foods (spicy foods, caffeine, alcohol, carbonated beverages); slow mindful eating; stress management (diaphragmatic breathing, yoga, meditation); and regular moderate exercise.

How the NSR-47 Protocol Addresses Functional Dyspepsia

The NSR-47 protocol targets both aspects of vagal dysfunction in FD. The 4-6 extended exhale pattern enhances vagal efferent activity, improving gastric accommodation. By raising baseline vagal tone over 28 days, the protocol also reduces visceral hypersensitivity by calming the afferent signaling pathways that amplify normal sensations into pain. Users often report less postprandial pain and improved meal tolerance.

When to See a Doctor

If you have chronic upper abdominal symptoms with normal endoscopy, consult a gastroenterologist familiar with disorders of gut-brain interaction. Seek immediate care for severe pain, vomiting, GI bleeding, or unintentional weight loss.